![Marisa Guitart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marisa Guitart
Corporate Officer/Principal en Sanifit Therapeutics SA .
Origen de la red de primer grado Marisa Guitart.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.
16
| Subsidiary | Biotechnology | 16 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Marisa Guitart a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Corporate Officer/Principal | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Phase4 Partners Ltd.
![]() Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Investment Committee Member | |
DIAMEDICA THERAPEUTICS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ASANTE SOLUTIONS INC | Medical Specialties | Director/Board Member | |
ALMIRALL, S.A. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Artax Biopharma, Inc.
![]() Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Founder | |
Oberlin College | College/University | Undergraduate Degree | |
Lundbeckfond Invest A/S
![]() Lundbeckfond Invest A/S Investment ManagersFinance Lundbeckfond Invest A/S (Lundbeckfond Invest) is the investment management subsidiary of the Lundbeck Foundation in Denmark. Established in 1999, the firm is based in Copenhagen and manages the Lundbeck Foundation's investments, aiming for long-term, stable returns with moderate risk, such that the Foundation's net capital is not jeopardized and the Foundation is able to meet its commitments in terms of awarding grants and of laying a capital base for its subsidiaries. | Investment Managers | Director/Board Member | |
Lundbeck Foundation
![]() Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Investment Trusts/Mutual Funds | Director/Board Member | |
Laboratorios Wassermann Sa
![]() Laboratorios Wassermann Sa Pharmaceuticals: OtherHealth Technology Part of Valline Srl, Laboratorios Wassermann Sa is a Spanish pharmaceutical company that manufactures pharmaceutical products. Laboratorios Wassermann was acquired by CHIESI Farmaceutici SpA on May 01, 1995. | Pharmaceuticals: Other | Corporate Officer/Principal | |
Laboratorios Salvat SA
![]() Laboratorios Salvat SA Pharmaceuticals: MajorHealth Technology Laboratorios Salvat develops and manufactures pharmaceutical products. It offers antiseptics, analgesics, antipyretics, and antibiotics. The company was founded in 1955 and is headquartered in Esplugues de Llobregat, Spain. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cornell University
![]() Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree | |
North Carolina State University | College/University | Undergraduate Degree | |
Technical University of Denmark | College/University | Graduate Degree | |
NEXSTIM PLC | Medical Specialties | Director/Board Member | |
University of Toledo Medical Center | College/University | Doctorate Degree | |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
DYSIS Medical Ltd.
![]() DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Medical Specialties | Director/Board Member | |
Ysios Capital Partners SGEIC SA
![]() Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder Private Equity Investor | |
Universidad de las Islas Baleares | College/University | Corporate Officer/Principal | |
REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Palau Pharma SA
![]() Palau Pharma SA BiotechnologyHealth Technology Palau Pharma SA is a holding company engaged in the discovery and development of biophamaceuticals for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, neuropathic pain, and chronic obstructive pulmonary disease. The company was founded on March 13, 1991 and is headquartered in Palau Solita i Plegamans, Spain. | Biotechnology | Corporate Officer/Principal | |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Niels Clauson-Kaas A/S
![]() Niels Clauson-Kaas A/S Miscellaneous Commercial ServicesCommercial Services Niels Clauson-Kaas A/S provides research and experimental development services in the fields of natural sciences and engineering. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
BIOM'UP | Medical Specialties | Director/Board Member | |
Lundbeckfonden Ventures
![]() Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Investment Managers | Consultant / Advisor | |
Chiltern International, Inc.
![]() Chiltern International, Inc. BiotechnologyHealth Technology Part of Laboratory Corp. of America Holdings, Chiltern International, Inc. is a contract research organization that offers clinical development, scientific services, and collaborative technologies. | Biotechnology | Corporate Officer/Principal | |
Medlumics SL
![]() Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
Columbus Venture Partners SGEIC SA
![]() Columbus Venture Partners SGEIC SA Investment ManagersFinance Columbus Venture Partners SGEIC SA (Columbus VP) is an independent Spanish venture capital firm which was founded in 2015 by Javier García Cogorro and Damià Tormo Carulla. The firm headquartered in Madri, Spain. | Investment Managers | Founder | |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
Center For Intelligent Research in Crystal Engineering SL
![]() Center For Intelligent Research in Crystal Engineering SL Miscellaneous Commercial ServicesCommercial Services Center For Intelligent Research in Crystal Engineering SL is based in Palma, Spain. CIRCE Scientific, also known as the Center For Intelligent Research in Crystal Engineering SL, achieves improved health and longevity through scientifically enhanced active ingredients with its Cocrystal Engineering. The Spanish company was founded by Fernando Barrera and Rafel Prohens. Fernando Barrera has been the CEO since incorporation. | Miscellaneous Commercial Services | Chairman | |
Highlight Therapeutics SL
![]() Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Founder | |
SpliceBio SL
![]() SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
George Washington University School of Medicine & Health | College/University | Graduate Degree | |
EDGEWISE THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
NuMat Medtech SL
![]() NuMat Medtech SL Miscellaneous Commercial ServicesCommercial Services NuMat Medtech SL engages in the development of coating technology for dental and orthopedic bone implants. It offers solutions based on natural molecules that improves functionalities on implants. The company was founded by Marta Monjo and Joana M. Ramis in 2016 and is headquartered in Palma de Mallorca, Spain. | Miscellaneous Commercial Services | Chairman | |
Tagworks Pharmaceuticals BV
![]() Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Biotechnology | Director/Board Member | |
Tyris Therapeutics SL
![]() Tyris Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Tyris Therapeutics SL provides business management consulting services. The company is based in Valencia, Spain. The Spanish company was founded in 2020. The CEO is Carulla Damià Tormo. | Miscellaneous Commercial Services | Chief Executive Officer | |
Sound Bioventures Management ApS | Investment Managers | Founder | |
Bioibal | President |
Estadísticas
Internacional
Estados Unidos | 17 |
España | 17 |
Dinamarca | 10 |
Países Bajos | 5 |
Reino Unido | 3 |
Sectorial
Health Technology | 31 |
Consumer Services | 8 |
Finance | 7 |
Commercial Services | 5 |
Miscellaneous | 2 |
Operativa
Director/Board Member | 80 |
Corporate Officer/Principal | 28 |
Private Equity Investor | 13 |
Founder | 10 |
Chief Executive Officer | 9 |
Las relaciones más conectadas
- Bolsa de valores
- Insiders
- Marisa Guitart
- Conexiones Empresas